Concepts (244)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Biofilms | 4 | 2019 | 304 | 1.44 | Why? |
| Lyme Neuroborreliosis | 1 | 2018 | 4 | 0.76 | Why? |
| Streptococcus pneumoniae | 4 | 2018 | 827 | 0.71 | Why? |
| Azo Compounds | 1 | 2017 | 39 | 0.67 | Why? |
| Nitric Oxide Donors | 1 | 2017 | 53 | 0.66 | Why? |
| Child Welfare | 1 | 2021 | 405 | 0.58 | Why? |
| Education | 1 | 2020 | 434 | 0.57 | Why? |
| Cephalosporins | 1 | 2017 | 250 | 0.56 | Why? |
| Prodrugs | 1 | 2017 | 264 | 0.55 | Why? |
| Anti-Bacterial Agents | 7 | 2019 | 10083 | 0.55 | Why? |
| Arthritis, Infectious | 1 | 2012 | 111 | 0.42 | Why? |
| Osteomyelitis | 1 | 2012 | 131 | 0.41 | Why? |
| Immunization, Secondary | 6 | 2021 | 1649 | 0.40 | Why? |
| Bacterial Infections | 3 | 2019 | 2229 | 0.39 | Why? |
| Haemophilus influenzae | 2 | 2018 | 196 | 0.34 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 1454 | 0.32 | Why? |
| Antibodies, Bacterial | 3 | 2018 | 510 | 0.29 | Why? |
| Schools | 2 | 2022 | 4187 | 0.29 | Why? |
| Immunogenicity, Vaccine | 4 | 2021 | 4624 | 0.28 | Why? |
| Surgical Procedures, Operative | 1 | 2019 | 2662 | 0.26 | Why? |
| Malaria, Falciparum | 2 | 2018 | 377 | 0.25 | Why? |
| Carrier State | 3 | 2019 | 2100 | 0.23 | Why? |
| Social Isolation | 1 | 2021 | 5932 | 0.21 | Why? |
| Pneumococcal Infections | 2 | 2017 | 562 | 0.21 | Why? |
| Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2017 | 64 | 0.21 | Why? |
| Nitric Oxide | 2 | 2017 | 769 | 0.20 | Why? |
| Single-Blind Method | 5 | 2021 | 1283 | 0.20 | Why? |
| Protozoan Proteins | 2 | 2018 | 205 | 0.20 | Why? |
| Bones of Lower Extremity | 1 | 2018 | 1 | 0.20 | Why? |
| Child | 14 | 2022 | 70012 | 0.19 | Why? |
| Syphilis, Congenital | 1 | 2018 | 13 | 0.19 | Why? |
| Prostheses and Implants | 1 | 2019 | 116 | 0.19 | Why? |
| Psychology, Child | 1 | 2021 | 206 | 0.18 | Why? |
| United Kingdom | 13 | 2021 | 18046 | 0.18 | Why? |
| Treponema pallidum | 1 | 2018 | 42 | 0.18 | Why? |
| Cystic Fibrosis | 2 | 2019 | 1104 | 0.18 | Why? |
| NF-kappa B p52 Subunit | 1 | 2017 | 24 | 0.18 | Why? |
| Bacterial Vaccines | 1 | 2019 | 139 | 0.18 | Why? |
| Psychology, Adolescent | 1 | 2021 | 208 | 0.18 | Why? |
| Streptococcal Vaccines | 1 | 2018 | 31 | 0.18 | Why? |
| Child, Preschool | 12 | 2020 | 36283 | 0.18 | Why? |
| Penicillinase | 1 | 2017 | 3 | 0.18 | Why? |
| Peptidoglycan | 1 | 2017 | 27 | 0.18 | Why? |
| Serogroup | 2 | 2017 | 510 | 0.17 | Why? |
| Plankton | 1 | 2017 | 8 | 0.17 | Why? |
| Poliovirus Vaccine, Inactivated | 1 | 2018 | 72 | 0.17 | Why? |
| Methionine | 1 | 2017 | 53 | 0.17 | Why? |
| Administration, Intravenous | 2 | 2018 | 1115 | 0.17 | Why? |
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2018 | 92 | 0.17 | Why? |
| Malaria Vaccines | 1 | 2018 | 90 | 0.17 | Why? |
| Haemophilus Infections | 1 | 2017 | 69 | 0.17 | Why? |
| Catheterization | 1 | 2019 | 264 | 0.17 | Why? |
| Genetic Vectors | 3 | 2020 | 1600 | 0.16 | Why? |
| Immunization Schedule | 2 | 2021 | 1305 | 0.16 | Why? |
| Neisseria meningitidis, Serogroup C | 1 | 2016 | 46 | 0.16 | Why? |
| Lyme Disease | 1 | 2018 | 102 | 0.16 | Why? |
| Haemophilus Vaccines | 1 | 2016 | 76 | 0.16 | Why? |
| Streptococcus agalactiae | 1 | 2018 | 194 | 0.16 | Why? |
| Sepsis | 1 | 2014 | 3517 | 0.16 | Why? |
| Amoxicillin | 1 | 2017 | 98 | 0.16 | Why? |
| Sirolimus | 1 | 2018 | 240 | 0.15 | Why? |
| Antigens | 1 | 2018 | 267 | 0.15 | Why? |
| Optimism | 1 | 2018 | 192 | 0.15 | Why? |
| Prosthesis-Related Infections | 1 | 2019 | 302 | 0.15 | Why? |
| Meningococcal Vaccines | 1 | 2018 | 225 | 0.15 | Why? |
| Tetanus Toxoid | 1 | 2016 | 136 | 0.15 | Why? |
| Pneumococcal Vaccines | 2 | 2018 | 571 | 0.15 | Why? |
| Catheter-Related Infections | 1 | 2019 | 381 | 0.15 | Why? |
| Meningococcal Infections | 1 | 2018 | 216 | 0.15 | Why? |
| Measles-Mumps-Rubella Vaccine | 1 | 2018 | 282 | 0.14 | Why? |
| Complement System Proteins | 1 | 2018 | 380 | 0.14 | Why? |
| Interferon-gamma Release Tests | 1 | 2017 | 253 | 0.14 | Why? |
| Streptococcal Infections | 1 | 2018 | 255 | 0.14 | Why? |
| Adolescent | 14 | 2021 | 86841 | 0.14 | Why? |
| Carrier Proteins | 1 | 2017 | 513 | 0.14 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.13 | Why? |
| Spleen | 1 | 2018 | 877 | 0.13 | Why? |
| Immunologic Deficiency Syndromes | 1 | 2018 | 368 | 0.13 | Why? |
| Liver | 2 | 2018 | 4007 | 0.13 | Why? |
| Policy Making | 1 | 2020 | 829 | 0.12 | Why? |
| Biological Specimen Banks | 1 | 2021 | 1142 | 0.12 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.12 | Why? |
| Pseudomonas Infections | 1 | 2017 | 425 | 0.12 | Why? |
| Latent Tuberculosis | 1 | 2017 | 324 | 0.12 | Why? |
| Infliximab | 1 | 2017 | 502 | 0.12 | Why? |
| Pseudomonas aeruginosa | 1 | 2017 | 652 | 0.12 | Why? |
| Infant | 6 | 2020 | 30274 | 0.11 | Why? |
| Dexamethasone | 2 | 2020 | 2055 | 0.11 | Why? |
| Nasal Mucosa | 1 | 2018 | 1218 | 0.10 | Why? |
| Humans | 41 | 2022 | 930598 | 0.10 | Why? |
| Systemic Inflammatory Response Syndrome | 2 | 2020 | 6653 | 0.10 | Why? |
| Critical Pathways | 1 | 2020 | 1587 | 0.10 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2021 | 1380 | 0.10 | Why? |
| Critical Care | 1 | 2014 | 14081 | 0.10 | Why? |
| Adenoviruses, Simian | 2 | 2020 | 52 | 0.10 | Why? |
| Epitopes | 2 | 2018 | 4113 | 0.09 | Why? |
| Antibody Formation | 2 | 2021 | 4038 | 0.09 | Why? |
| Research | 1 | 2021 | 2115 | 0.09 | Why? |
| Respiratory Tract Infections | 2 | 2019 | 6817 | 0.09 | Why? |
| Immunologic Memory | 2 | 2017 | 3362 | 0.09 | Why? |
| Hospitals, Pediatric | 1 | 2018 | 1792 | 0.09 | Why? |
| Antibodies, Protozoan | 2 | 2018 | 121 | 0.08 | Why? |
| Prenatal Care | 1 | 2018 | 1314 | 0.08 | Why? |
| Bacteria | 1 | 2018 | 1897 | 0.08 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.08 | Why? |
| Young Adult | 11 | 2021 | 93724 | 0.08 | Why? |
| Autoantibodies | 1 | 2017 | 2094 | 0.08 | Why? |
| Outpatients | 1 | 2018 | 3417 | 0.07 | Why? |
| Vaccinia virus | 2 | 2018 | 346 | 0.07 | Why? |
| Pediatrics | 1 | 2021 | 2969 | 0.07 | Why? |
| Infant, Newborn | 4 | 2018 | 23105 | 0.07 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.07 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.07 | Why? |
| Age Factors | 3 | 2020 | 21039 | 0.07 | Why? |
| Asymptomatic Infections | 2 | 2021 | 7218 | 0.07 | Why? |
| Viruses | 1 | 2018 | 2238 | 0.07 | Why? |
| Vaccines, Conjugate | 2 | 2017 | 328 | 0.07 | Why? |
| Glucocorticoids | 1 | 2020 | 4431 | 0.07 | Why? |
| Plasmodium falciparum | 2 | 2018 | 337 | 0.07 | Why? |
| Antibodies, Neutralizing | 3 | 2021 | 25288 | 0.07 | Why? |
| Female | 21 | 2021 | 380317 | 0.06 | Why? |
| Male | 19 | 2021 | 367725 | 0.06 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.06 | Why? |
| Students | 1 | 2021 | 5255 | 0.06 | Why? |
| Vaccination | 5 | 2019 | 19050 | 0.06 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.06 | Why? |
| Pregnancy Complications, Infectious | 2 | 2018 | 11559 | 0.06 | Why? |
| Administration, Oral | 2 | 2020 | 2340 | 0.06 | Why? |
| Antirheumatic Agents | 1 | 2017 | 3023 | 0.06 | Why? |
| Azithromycin | 1 | 2017 | 3943 | 0.06 | Why? |
| Equivalence Trials as Topic | 1 | 2021 | 242 | 0.05 | Why? |
| Pandemics | 8 | 2022 | 389249 | 0.05 | Why? |
| Tertiary Care Centers | 1 | 2018 | 8248 | 0.05 | Why? |
| Mutation | 2 | 2018 | 12376 | 0.05 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.05 | Why? |
| Intention to Treat Analysis | 1 | 2021 | 673 | 0.05 | Why? |
| Attitude of Health Personnel | 1 | 2018 | 4741 | 0.05 | Why? |
| Adrenal Cortex Hormones | 1 | 2017 | 6537 | 0.05 | Why? |
| Penicillin V | 1 | 2018 | 10 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2018 | 6331 | 0.05 | Why? |
| Injections, Intravenous | 1 | 2020 | 381 | 0.05 | Why? |
| Analgesics, Non-Narcotic | 1 | 2020 | 164 | 0.05 | Why? |
| Lyme Disease Vaccines | 1 | 2018 | 3 | 0.05 | Why? |
| Education, Distance | 1 | 2020 | 4956 | 0.05 | Why? |
| Heterotaxy Syndrome | 1 | 2018 | 18 | 0.05 | Why? |
| Patient Acceptance of Health Care | 1 | 2018 | 5002 | 0.05 | Why? |
| Viral Vaccines | 1 | 2020 | 7560 | 0.05 | Why? |
| Biosynthetic Pathways | 1 | 2018 | 97 | 0.05 | Why? |
| Vaccinia | 1 | 2018 | 32 | 0.05 | Why? |
| Borrelia burgdorferi | 1 | 2018 | 31 | 0.05 | Why? |
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 43 | 0.05 | Why? |
| Adult | 13 | 2022 | 244371 | 0.04 | Why? |
| Respiration, Artificial | 2 | 2020 | 22116 | 0.04 | Why? |
| Vaccines, Combined | 1 | 2018 | 67 | 0.04 | Why? |
| Treatment Outcome | 3 | 2020 | 51732 | 0.04 | Why? |
| Registries | 1 | 2018 | 12327 | 0.04 | Why? |
| Antigens, Protozoan | 1 | 2018 | 121 | 0.04 | Why? |
| Tetanus | 1 | 2018 | 61 | 0.04 | Why? |
| Middle Aged | 13 | 2021 | 270681 | 0.04 | Why? |
| Blood Bactericidal Activity | 1 | 2016 | 19 | 0.04 | Why? |
| Acetaminophen | 1 | 2020 | 326 | 0.04 | Why? |
| Diphtheria | 1 | 2018 | 74 | 0.04 | Why? |
| Nasopharynx | 1 | 2017 | 10224 | 0.04 | Why? |
| Poliovirus | 1 | 2018 | 109 | 0.04 | Why? |
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2018 | 91 | 0.04 | Why? |
| Bacterial Load | 1 | 2017 | 179 | 0.04 | Why? |
| Gene Expression Regulation, Bacterial | 1 | 2017 | 143 | 0.04 | Why? |
| Heterozygote | 1 | 2017 | 249 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Pedigree | 1 | 2017 | 502 | 0.04 | Why? |
| Ceftriaxone | 1 | 2018 | 365 | 0.04 | Why? |
| Microbiological Techniques | 1 | 2018 | 232 | 0.04 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.04 | Why? |
| Immunoglobulin G | 4 | 2021 | 21571 | 0.04 | Why? |
| Whooping Cough | 1 | 2018 | 201 | 0.04 | Why? |
| Cytokines | 1 | 2017 | 15010 | 0.04 | Why? |
| Interleukin-2 | 1 | 2017 | 443 | 0.04 | Why? |
| Academies and Institutes | 1 | 2018 | 539 | 0.03 | Why? |
| Treatment Failure | 1 | 2020 | 2106 | 0.03 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.03 | Why? |
| Poliomyelitis | 1 | 2018 | 263 | 0.03 | Why? |
| Genome, Bacterial | 1 | 2017 | 446 | 0.03 | Why? |
| Aged | 8 | 2021 | 215776 | 0.03 | Why? |
| Interdisciplinary Communication | 1 | 2020 | 1425 | 0.03 | Why? |
| Counseling | 1 | 2018 | 747 | 0.03 | Why? |
| Recombination, Genetic | 1 | 2018 | 1265 | 0.03 | Why? |
| Risk Factors | 1 | 2020 | 71621 | 0.03 | Why? |
| Europe | 2 | 2018 | 12702 | 0.03 | Why? |
| Anti-HIV Agents | 1 | 2004 | 2209 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2020 | 4260 | 0.03 | Why? |
| South Africa | 1 | 2020 | 3326 | 0.03 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2021 | 10649 | 0.03 | Why? |
| Aged, 80 and over | 4 | 2020 | 88759 | 0.02 | Why? |
| Double-Blind Method | 1 | 2020 | 5988 | 0.02 | Why? |
| Biopsy | 1 | 2018 | 2811 | 0.02 | Why? |
| Sputum | 1 | 2017 | 1720 | 0.02 | Why? |
| Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.02 | Why? |
| Anti-Infective Agents | 1 | 2020 | 1766 | 0.02 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.02 | Why? |
| Bacterial Proteins | 1 | 2017 | 1318 | 0.02 | Why? |
| Immunization | 1 | 2017 | 2019 | 0.02 | Why? |
| Patient Education as Topic | 1 | 2018 | 1476 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2017 | 2830 | 0.02 | Why? |
| Health Care Surveys | 1 | 2018 | 2942 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Whole Genome Sequencing | 1 | 2018 | 3239 | 0.02 | Why? |
| State Medicine | 1 | 2021 | 2847 | 0.02 | Why? |
| Fatigue | 1 | 2018 | 2479 | 0.02 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2021 | 3388 | 0.02 | Why? |
| Interferon-gamma | 1 | 2017 | 2711 | 0.02 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2017 | 2483 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2020 | 7268 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2017 | 2585 | 0.02 | Why? |
| Consensus | 1 | 2020 | 6345 | 0.02 | Why? |
| Pregnancy | 2 | 2018 | 23879 | 0.02 | Why? |
| Artificial Intelligence | 1 | 2021 | 3543 | 0.02 | Why? |
| Prevalence | 2 | 2017 | 25773 | 0.02 | Why? |
| Spain | 1 | 2022 | 15545 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2018 | 6740 | 0.02 | Why? |
| Brazil | 1 | 2020 | 12582 | 0.02 | Why? |
| Antibodies, Viral | 3 | 2021 | 51949 | 0.02 | Why? |
| T-Lymphocytes | 1 | 2020 | 6670 | 0.02 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2017 | 4545 | 0.02 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.01 | Why? |
| Ultrasonography | 1 | 2018 | 4409 | 0.01 | Why? |
| Magnetic Resonance Imaging | 1 | 2018 | 6551 | 0.01 | Why? |
| Societies, Medical | 1 | 2018 | 6907 | 0.01 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2018 | 5837 | 0.01 | Why? |
| Virus Diseases | 1 | 2018 | 3779 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.01 | Why? |
| Viral Load | 1 | 2021 | 15850 | 0.01 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.01 | Why? |
| Animals | 2 | 2019 | 78931 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.01 | Why? |
| HIV Infections | 1 | 2004 | 11620 | 0.01 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.01 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 8811 | 0.01 | Why? |
| Anxiety | 1 | 2021 | 17311 | 0.01 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.01 | Why? |
| Forecasting | 1 | 2004 | 4492 | 0.01 | Why? |
| Clinical Competence | 1 | 2004 | 3263 | 0.01 | Why? |
Faust's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(244)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(276)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_